Multiple Myeloma (State of the Art Series)

Multiple myeloma is the second most common hematologic malignancy, affecting over 14,000 patients per year in the USA. Over the last ten years, there has been a dramatic increase in our understanding of the biology of multiple myeloma, which has provided insights into mechanisms of cytotoxic resistance, both as inherent characteristics of the myeloma cell and the protective interaction between the tumor and its bone marrow microenvironment. Through this greater understanding, a large array of new therapies has been engendered and a significant impact is being made on patient outcome as a result. This second edition of "Multiple Myeloma" has been revised and updated to provide a concise overview of the state of the art in this field.